Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Alpha Teknova Q3 revenue beats estimates on customer segment growth, lifts 2026 outlook

By Reuters News


Overview

  • US reagents producer's Q3 revenue rose 22% yr/yr, beating analyst expectations

  • Company raised 2026 revenue guidance to $46-48 mln

  • Completed $46 mln public equity offering in October to strengthen balance sheet


Outlook

  • Alpha Teknova raises 2026 revenue guidance to $46-48 mln

  • Company maintains 2026 Free Cash Outflow guidance of less than $8 mln


Result Drivers

  • CUSTOMER SEGMENT GROWTH - Co said revenue growth was driven by increased sales to life science tools and diagnostics, and biopharma customers, with higher purchases of custom products by small and mid-sized biotech firms and their contract manufacturers

  • CLINICAL SOLUTIONS SURGE - Clinical Solutions revenue rose 86% yr/yr, outpacing Lab Essentials growth

  • GROSS MARGIN IMPROVEMENT - Gross margin increased to 38.0% from 30.7%, mainly due to higher revenue and lower fixed cost absorption, partially offset by higher variable costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$12.70 mln

$11.64 mln (7 Analysts)

Q3 Loss Per Share

$0.06

Q3 Net Loss

$3.49 mln

Q3 Gross Profit

$4.83 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Alpha Teknova, Inc. is $9.50, about 29.4% above its November 3 closing price of $7.34


Reuters Recommended Reads

  • Nov 3 - Stevanato Group Q3 revenue beats estimates on biopharma segment

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 3 - Biomérieux third-quarter organic sales growth beats expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.